Practitioners

Thank you for supporting cervical cancer research.​ Trial recruitment is now complete. All patients will have completed follow-up in this trial by December 2026.

HPV and Cervical Cancer

This is the first large scale clinical trial internationally to assess primary HPV DNA testing and Liquid Based Cytology screening tests in a popultation that is highly vaccinated against HPV. A total of 76,000 women consented into the trial, making it the largest randomised controlled trial in Australia.

Primary HPV DNA testing has been reviewed and endorsed as a primary cervical screening method by the International Agency for Research on Cancer.A number of large scale randomised controlled trials of primary HPV DNA screening have found that HPV screening is more sensitive in detecting precancerous lesions than cytology-based screening and that it can safely be conducted at a longer interval (see fig 1). However to date there have been no specific trials that support primary HPV DNA testing for cervical screening in the Australian context.

For more information, please contact Compass Trial staff on 1800 611 635.

Fig 1. Kaplan-Meier plots of cumulative incidence rate for CIN3+ for women according to baseline test results in first 72 months of follow-up, excluding Denmark and Tübingen.

Dillner J et al. BMJ 2008;337:bmj.a1754 ©2008 by British Medical Journal Publishing Group

This is the first large scale clinical trial internationally to assess primary HPV DNA testing and Liquid Based Cytology screening tests in a population that is highly vaccinated against HPV. 

From mid-2021, Compass trial participants attending for their HPV exit test may be offered the option to access HPV self-collection.

Prior to recruiting women on to the COMPASS Trial it is imperative to review your medical indemnity cover.

Compass-PLUS is a questionnaire based research study within the Compass Trial.

During the study, the investigators and participating practitioners will be responsible for detecting and documenting events meeting the criteria and definition of an adverse event (AE) or serious adverse event (SAE).

Practice Pack

Trial information

Regular cervical screening is the best way to prevent cervical cancer in all women and people with a cervix

Self-collection is another option that is now available for cervical screening, and involves taking your own swab from the vagina. Find out more about self-collection here

Understand what happens if HPV is found on your Cervical Screening Test and what happens if more tests are needed.

ACPCC is a not-for-profit organisation and only charges patients the Medicare Schedule fee for pathology services, with only a small gap amount payable. 

READ UP ON IT

Related News Article

ECC2024 Melbourne The Eliminating Cervical Cancer 2024 (ECC2024) Conference, scheduled for 27th to 29th November in Melbourne, marks a pivotal moment in the global fight against cervical cancer. At this conference, the expansion of Australian expertise…
In September 2024, a nationwide, government-funded cervical screening campaign promoting self-collection is commencing and is expected to result in a substantial increase in patient demand. The ACPCC is supporting healthcare providers to prepare for…
Previous
Next

SELF COLLECTION

Screening Processes

Et has minim elitr intellegat. Mea aeterno eleifend.Et has minim elitr intellegat. Mea aeterno eleifend.Et has minim elitr inte
llegat. Mea aeterno eleifend.Et has minim elitr intellegat. Mea aeterno eleifend.Et has minim elitr intellegat. Mea aeterno eleifend.

READ UP ON IT

Success Stories

Providing access to immunisation for vulnerable groups (PAIVnG). Refugees and asylum seekers arrive in…